President Trump's Major Marijuana Move: What It Means for Canopy Growth, Green Thumb, and Tilray
2026-07-17 09:30
•Eric Volkman •The Motley Fool
••• •• Axe Capital view
Trump’s Marijuana Rescheduling: Little Impact on South African Investors
The U.S. move to ease medical cannabis restrictions offers minimal change for top cannabis stocks with limited direct South African connections.
President Trump’s executive order to shift medical marijuana from Schedule I to III might sound like a green light for cannabis investors, but for major players like Canopy Growth and Tilray, it’s a mixed bag. Canopy’s U.S. medical operations are tucked away in an affiliate that’s not consolidated in its main accounts due to Nasdaq rules. This means the potential IRS tax relief won’t boost its South African-listed earnings or share price notably. Tilray’s U.S. footprint is mostly craft beer, not cannabis, so it remains on the sidelines of this policy change. Locally, the JSE cannabis exposure is minimal, leaving USD/ZAR and sectors like pharmaceuticals or consumer discretionary to react marginally if at all. Watch the rand for signals; a significant move could hint at shifting risk appetite around emerging market assets. I’d watch cannabis stocks for now and focus on more directly impacted sectors in South Africa. this is just my opinion and not financial advice
Avoid chasing cannabis stocks on this news alone. Instead, keep an eye on the rand’s movement against the dollar as a barometer of local investor confidence and opportunistically explore banks or retailers benefiting from economic recovery.
- USD/ZAR
- Canopy Growth (CGC)
- US federal policy shifts reversing or stalling
- Rand volatility undermining investor sentiment
5/10
President Trump's executive order to reschedule medical marijuana from Schedule I to Schedule III provides limited benefits to major cannabis companies. While the rescheduling eliminates IRS Section 280E tax restrictions for medical marijuana businesses, it only applies to medical products, not the larger recreational market. Canopy Growth, Tilray, and Green Thumb Industries face minimal direct impact due to their business structures and market focus, though the change creates new regulatory compliance burdens.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Eric Volkman
Categories: Equities, Earnings, Financials
Tickers: CGC, TLRY
Sentiment: Neutral - While the company has medical marijuana operations through its affiliate Canopy USA, it does not consolidate these financials due to Nasdaq restrictions, resulting in no direct financial impact from rescheduling. Medical sales represent a portion of revenue but the structural separation limits benefits. The company has growing international medical marijuana sales but cannot directly export to the U.S. market. Its U.S. operations focus on craft beer, not cannabis, making the rescheduling largely irrelevant to its business fundamentals.
Keywords: marijuana rescheduling, Schedule III, medical cannabis, IRS Section 280E, cannabis stocks, regulatory compliance, recreational marijuana
Insights:
- CGC: Neutral: While the company has medical marijuana operations through its affiliate Canopy USA, it does not consolidate these financials due to Nasdaq restrictions, resulting in no direct financial impact from rescheduling. Medical sales represent a portion of revenue but the structural separation limits benefits.
- TLRY: Neutral: The company has growing international medical marijuana sales but cannot directly export to the U.S. market. Its U.S. operations focus on craft beer, not cannabis, making the rescheduling largely irrelevant to its business fundamentals.